Docket Number: ENP-057



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Frank X.H. Wu et al.

Art Unit : **TBD** Examiner: TBD

Serial No.:

10/613,206

Filed

July 3, 2003

Title

: Aza-Peptide Macrocyclic Hepatitis C Serine Protease Inhibitors

Mail Stop Non-Fee Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

Applicants would also like to bring to the Examiner's attention the following copending, commonly-assigned patent applications: 10/365,854 (filed Feb. 13, 2003), 10/360,947 (filed Feb. 7, 2003), 10/384,120 (filed Mar. 7, 2003), 10/454,97 (filed June 5, 2003), and 10/418,759 (filed April 18, 2003).

No fee is believed to be due. In the event that a fee is due please charge Enanta Pharmaceuticals, Inc., Deposit Account No. 50-2010, referencing Attorney Docket No. ENP-057.

Respectfully submitted,

Enanta Pharmaceuticals, Inc.

Attn: Patent Dept. 500 Arsenal Street Watertown, MA 02472

D. Ferrone Rég. No. 52,887


CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Signature

Date of De

Typed or Printed Name of Person Signing Certificate



TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Docket No. ENP-057

(Under 37 CFR 1.97(b) or 1.97(c))

In Re Application Of: Wu, et al.

Serial No. 10/613,206

Filing Date
July 3, 2003

Examiner TBD

Group Art Unit TBD

Title: Aza-Peptide Macrocyclic Hepatitis C Serine Protease Inhibitors

Address to:

Assistant Commissioner for Patents Washington, D.C. 20231

37 CFR 1.97(b)

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

or

37 CFR 1.97(c)

The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Office Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by on of:

the statement specified in 37 CFR 1.97(e);

or

the fee set forth in 37 CFR 1.17(p).

ENP057 OCT 0 9 2003

rm Pto-1449 U.S. DEPARTMENT OF COMMERCE				ATTY. DOCKET NO.	SERIAL NO.	SERIAL NO.			
Rev. 2-32 PATENT AND TRADEMARK OFFICE				ENP-057	10/6	10/613,206			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use s v ral she ts if necessary)				Frank X.H. Wu et al.					
				FILING DATE	GROUP	GROUP			
				July 3, 2003		1624			
			U.S. PATEN	IT DOCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	AA	US 2002/0037998 A1	3/28/2002	Llinas-Brunet et al.	530	331	5/4/20	01	
	AB	U.S. Patent 6,608,027	8/19/2003	Tsantrizos et al.			1/16/2001		
		FO	REIGN PAT	ENT DOCUMENTS					
							TRANS		
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
	ВА	WO 00/059929	10/12/2000	PCT	C07K	5/08			
	вв	WO 03/053349	12/20/2001	PCT					
		OTHER DOCUMENTS (Including A	uthor, Title, Date, Perti	nent Page	s, etc.)			
						.v			
EXAMINER				DATE CONSIDERED					